$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028453 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$300.2K	$19.74K	$1.310K
YoY Change	26007.48%	1406.72%
Cost Of Revenue	$74.70K	$1.234K	$150.00
YoY Change	51067.12%	722.67%
Gross Profit	$223.8K	$18.50K	$1.160K
YoY Change	22166.67%	1495.17%
Gross Profit Margin	74.53%	93.75%	88.55%
Selling, General & Admin	$2.024M	$1.426M	$349.4K
YoY Change	239.31%	308.25%	44.02%
% of Gross Profit	904.42%	7708.98%	30121.55%
Research & Development	$330.4K	$335.1K	$335.9K
YoY Change	3.33%	-0.22%	17.05%
% of Gross Profit	147.63%	1811.09%	28954.31%
Depreciation & Amortization	$23.50K	$21.00K	$1.040K
YoY Change	2951.95%	1919.23%	-12.61%
% of Gross Profit	10.5%	113.49%	89.66%
Operating Expenses	$2.518M	$1.797M	$685.3K
YoY Change	157.71%	162.21%	29.4%
Operating Profit	-$2.295M	-$1.778M	-$684.1K
YoY Change	135.06%	159.95%	29.18%
Interest Expense	$8.785K	$1.360K	$383.8K
YoY Change	-99.01%	-99.65%	-78.33%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$42.76K
YoY Change
Pretax Income	-$2.289M	-$1.736M	-$88.05K
YoY Change	-53.48%	1871.14%	-105.95%
Income Tax	$2.294K	$4.587K	$0.00
% Of Pretax Income
Net Earnings	-$2.291M	-$1.740M	-$88.05K
YoY Change	-53.43%	1876.35%	-105.95%
Net Earnings / Revenue	-763.03%	-8816.36%	-6721.37%
Basic Earnings Per Share	-$0.26	-$0.20	-$0.03
Diluted Earnings Per Share	-$0.26	-$0.20	-$32.28K
COMMON SHARES
Basic Shares Outstanding	8.783M shares	8.519M shares	2.694M shares
Diluted Shares Outstanding	8.697M shares	8.521M shares	2.694M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.510M	$8.279M	$214.4K
YoY Change	-66.59%	3761.56%
Cash & Equivalents	$4.500M	$8.300M	$214.4K
Short-Term Investments
Other Short-Term Assets	$380.0K	$279.7K	$99.37K
YoY Change	-29.8%	181.45%
Inventory	$9.908K	$10.10K	$5.660K
Prepaid Expenses
Receivables	$1.110M	$90.23K	$7.820K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.010M	$8.659M	$327.3K
YoY Change	-57.24%	2546.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$512.2K	$207.4K	$2.550K
YoY Change	28656.43%	8032.43%
Goodwill	$1.149M
YoY Change
Intangibles	$848.1K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.06K	$6.920K	$611.0K
YoY Change	167.67%	-98.87%
Total Long-Term Assets	$4.179M	$214.3K	$613.5K
YoY Change	53611.03%	-65.07%
TOTAL ASSETS
Total Short-Term Assets	$6.010M	$8.659M	$327.3K
Total Long-Term Assets	$4.179M	$214.3K	$613.5K
Total Assets	$10.19M	$8.873M	$940.8K
YoY Change	-27.54%	843.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$827.4K	$174.4K	$585.2K
YoY Change	452.09%	-70.19%
Accrued Expenses	$643.8K	$515.7K	$1.975M
YoY Change	35.81%	-73.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$42.33K	$11.12M
YoY Change	-100.0%	-99.62%
Long-Term Debt Due	$360.0K
YoY Change
Total Short-Term Liabilities	$1.959M	$775.2K	$13.68M
YoY Change	33.77%	-94.33%
LONG-TERM LIABILITIES
Long-Term Debt	$930.0K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$310.0K
YoY Change
Total Long-Term Liabilities	$1.240M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.959M	$775.2K	$13.68M
Total Long-Term Liabilities	$1.240M	$0.00	$0.00
Total Liabilities	$3.196M	$775.2K	$13.68M
YoY Change	118.25%	-94.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$42.20M	-$39.90M
YoY Change	20.57%
Common Stock	$64.54K	$59.89K
YoY Change	10.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.994M	$8.098M	-$12.74M
YoY Change
Total Liabilities & Shareholders Equity	$10.19M	$8.873M	$940.8K
YoY Change	-27.54%	843.24%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.291M	-$1.740M	-$88.05K
YoY Change	-53.43%	1876.35%	-105.95%
Depreciation, Depletion And Amortization	$23.50K	$21.00K	$1.040K
YoY Change	2951.95%	1919.23%	-12.61%
Cash From Operating Activities	-$1.530M	-$1.360M	-$376.1K
YoY Change	-13.07%	261.55%	3.72%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$3.870K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$2.190M
YoY Change
Cash From Investing Activities	-$2.180M	-$3.870K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-50.00K	-126.1K	-437.5K
YoY Change	-100.33%	-71.18%	-167.31%
NET CHANGE
Cash From Operating Activities	-1.530M	-1.360M	-376.1K
Cash From Investing Activities	-2.180M	-3.870K
Cash From Financing Activities	-50.00K	-126.1K	-437.5K
Net Change In Cash	-3.760M	-1.490M	-813.6K
YoY Change	-128.31%	83.12%	-383.16%
FREE CASH FLOW
Cash From Operating Activities	-$1.530M	-$1.360M	-$376.1K
Capital Expenditures	$0.00	$3.870K
Free Cash Flow	-$1.530M	-$1.364M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001712762
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Accretion Expense AccretionExpense		usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	BIAF	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41463
	dei	Entity Registrant Name EntityRegistrantName	bioAffinity Technologies, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5211056
	dei	Entity Address Address Line1 EntityAddressAddressLine1	22211 W. Interstate 10
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1206
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Antonio
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78257
	dei	City Area Code CityAreaCode	(210)
	dei	Local Phone Number LocalPhoneNumber	698-5334
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8782548	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8279182	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11413759	usd
CY2023Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	90233	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	10489	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	10101	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5540	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	279687	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	8659203	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11961687	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	207377	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6920	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	usd
CY2023Q2	us-gaap	Assets Assets	8873499	usd
CY2022Q4	us-gaap	Assets Assets	12182125	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	174404	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	345042	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	515663	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	42750	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	42334	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	251746	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	775151	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1138682	usd
CY2023Q2	us-gaap	Liabilities Liabilities	775151	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1138682	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8555365	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8555365	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8381324	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	59887	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	58669	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47978892	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47652242	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39940431	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36667468	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8098348	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8873499	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12182125	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19738	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1306	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20659	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1306	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1234	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	146	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1322	usd
	us-gaap	Cost Of Revenue CostOfRevenue	146	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	18504	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1160	usd
	us-gaap	Gross Profit GrossProfit	19337	usd
	us-gaap	Gross Profit GrossProfit	1160	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	335125	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	248419	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	704741	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	528267	usd
CY2023Q2	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	35260	usd
CY2022Q2	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	28240	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	54888	usd
	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	80744	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1426469	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	408619	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2596027	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	803311	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1796854	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	685279	usd
	us-gaap	Operating Expenses OperatingExpenses	3355657	usd
	us-gaap	Operating Expenses OperatingExpenses	1412322	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1778350	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-684119	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3336320	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1411162	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	44124	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	276	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	82778	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	847	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	1360	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	399265	usd
	us-gaap	Interest Expense InterestExpense	3015	usd
	us-gaap	Interest Expense InterestExpense	1546848	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
CY2022Q2	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	782798	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	1186992	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1735586	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88052	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3256557	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1557913	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4587	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16406	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2159	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1740173	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-88052	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3272963	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1560072	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8520714	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8520714	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2693511	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2693511	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8477656	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8477656	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2687431	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2687431	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	327868	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3272963	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8098348	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9668266	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	170255	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1740173	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8098348	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	132732	usd
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	213942	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	217973	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1560072	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16786329	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-16724777	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-16724777	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	26685	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-185	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-88052	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16786329	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-16786329	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3272963	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1560072	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	43236	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2079	usd
	us-gaap	Accretion Expense AccretionExpense	1205255	usd
	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	1186992	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	327868	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	132732	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	79743	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	6287	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4561	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5657	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-251292	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-28304	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-170638	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	354560	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-26231	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-42730	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	337566	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	42750	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2888990	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1010108	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36175	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36175	usd
	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	209412	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	100000	usd
	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	65031	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	475000	usd
	BIAF	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	520506	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	55651	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-209412	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-136126	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3134577	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1146234	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1360638	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8279182	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	214404	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16406	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2159	usd
	us-gaap	Interest Paid Net InterestPaidNet	3015	usd
	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	217973	usd
	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes	213942	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39900000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8300000	usd
CY2023Q2	BIAF	Total Assets Percent TotalAssetsPercent	0.93	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zEo7qEybsRhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zazF4RIR0yqh">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation allowance on the Company’s deferred tax assets, and the useful lives of fixed assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zQ9Eg4MXEiy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zev9RkLmshg">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zpzKvjpL8Ig8" title="Insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Advertising Expense AdvertisingExpense	28000	usd
	us-gaap	Advertising Expense AdvertisingExpense	3000	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	22000	usd
CY2022Q2	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5556344	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6270736	shares
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	104294	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	340078	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zs9LLJzwyoxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zyJPMmvdBIQ6">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $<span id="xdx_906_ecustom--ReclassifiedPatentExpensesAndAnnuityCosts_c20220101__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_zc4Z7pwokgZe" title="Reclassified patent expenses and annuity costs">101,000</span> and $<span id="xdx_907_ecustom--ReclassifiedPatentExpensesAndAnnuityCosts_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_zhSNu4w8jlq2" title="Reclassified patent expenses and annuity costs">59,000</span> from research and development to selling, general and administrative for the six months and three months ended June 30, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	47200	usd
CY2022Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	72048	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	128193	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	119773	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	279687	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	276519	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	340680	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	179416	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	144440	usd
CY2023Q2	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	54728	usd
CY2022Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	50922	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5852	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	515663	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2000000	shares
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	519794	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	483618	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	312417	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	269180	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	207377	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
	us-gaap	Depreciation Depreciation	41000	usd
	us-gaap	Depreciation Depreciation	2000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	21000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	43000	usd
	us-gaap	Payments For Rent PaymentsForRent	53000	usd
	us-gaap	Payments For Rent PaymentsForRent	26000	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	26000	usd
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	13000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285715	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8555365	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	170255	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26685	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	327868	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	132732	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.84
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	143023	shares
CY2022Q1	us-gaap	Share Price SharePrice	4.62
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.639	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0220	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares

Files In Submission

Name	View Source	Status
0001493152-23-028453-index-headers.html	Edgar Link	pending
0001493152-23-028453-index.html	Edgar Link	pending
0001493152-23-028453.txt	Edgar Link	pending
0001493152-23-028453-xbrl.zip	Edgar Link	pending
biaf-20230630.xsd	Edgar Link	pending
ex3-2.htm	Edgar Link	pending
ex3-2_001.jpg	Edgar Link	pending
ex3-2_002.jpg	Edgar Link	pending
ex3-4.htm	Edgar Link	pending
ex3-4_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
biaf-20230630_cal.xml	Edgar Link	unprocessable
biaf-20230630_def.xml	Edgar Link	unprocessable
biaf-20230630_lab.xml	Edgar Link	unprocessable
biaf-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2023 Q3 Form 10-Q Financial Statement

#000149315223028453 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2023 Q3 Form 10-Q Financial Statement

#000149315223028453 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf